Company Profile
WuXi AppTec
— A major chemistry services company handling small molecules, peptides, and nucleic acids from research through mass production—and facing U.S. regulatory scrutiny
WuXi AppTec is headquartered in Shanghai, ChinaContract research, development and manufacturing of pharmaceutical productsComment Our company does not have new medicines, from biotech, pharmaceutical companies worldwideSyn of candidate compounds, pre ical testing, production of original drugs and preparationsContact Us The company connects this from research (R) to development (D) and manufacturing (M)「CRDMO」Contact Us What is important from drug discovery and DDS?Oligonucleotide (nucleic acid) and peptideIn 2025, the TIDES business expanded to $13.7 billion (previous year +96.0%), Reaction tank of solid phase peptideOver 100,000LI've been increasing. On the other hand, in June 2026, the U.S. Department of Defense puts the company on the "China Military Enterprise" list (1260H list), the company prosecuts it as an error, and in AugustI got. The laws that restrict the procurement with U.S. biotechnology companies established in December 2025 (85SECURE Law, Article 851) are linked with this list.As of September 2026, procurement is not yet started。
- WuXi AppTec and DDS
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Company size
- Drug discovery and DDS resources
- Past Initiatives
- Future Plans and Handling of US SECURE Law
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. WuXi AppTec in 30 seconds and standing position in drug discovery and DDS
Hong Kong 2359Listed in 2018
（CRDMO）Never have your own medicines
OrigonucleotidePeptides and Nucleic Acids
Over 100,000LSeptember 2025
→ Get temporary closureThe Federal District Court was designated in June 2026 and in August
Businesses related to drug discovery and DDS are largePharmaceutical Company / Biotech / Contract Development Manufacturing (Research)3 types. WuXi AppTecContract research, development and manufacturingMoreStrong in chemical (low , peptide, nucleic acid)Company Profile FactsHome “WuXi。” of chemistry accounted for 364.7 billion yuan among the sales of co。ity business in 2025. Samsung and Samsung Biologics, which make antibody cells, is the strength of the companyWe make a lot of compounds and receive candidates from them to mass production.Flow According to the annual report, 310 molecules were transferred from the research stage to the development stage by synthesis more than 420,000 new compounds in 2025. This series of technical commentary “Peptides and GLP-1”, “nucleic acid drugs” and “CDMO”.
2. Logo and company name
WuXi AppTec。 In this article, we do not reproduce the generated image,
Logo displayed at the top of the official website (SVG)Home img/wuxi_apptec_logo.svg installed as a dark background.
Naming note: the company’s Chinese name is commonly romanized as Yaoming Kangde; in Japanese it is also written as “WuXi AppTec.” Antibody development and manufacturing WuXi BiologicsADC WuXi XDC Homeanother companynot a subsidiary of WuXi AppTec (WuXi XDC is an affiliated company investing 18.55% by WuXi AppTec). Since there are multiple companies that are "WuXi", this article distinguishes WuXi AppTec and other companies.
Official Site:https://www.wuxiapptec.com/3. Where is this company in the world of drug discovery and DDS?
TypeContract research, development and manufacturing (CRDMO)Home Business is divided into three categories Facts。
| Category | Home | Relationship with Drug and DDS |
|---|---|---|
| WuXi Chemistry | Development and manufacturing of low doses (R),TIDES | ThisHome Consignment of original medicine and preparation, peptide, nucleic acid, and chemical binding |
| WuXi Testing | Drug safety assessment, drug delivery (DMPK), analysis of biological samples | Evaluation of nucleic acids, connectives, polypropylene antibodies and peptides. New modalities exceed 35% of sales (late 2026) |
| WuXi Biology | Drug discovery support through clinical evaluations in test tubes and animals | New modalities (nucleic acids, antibody bindings, peptides, etc.) exceed 35% of sales (ear 2026) |
4. Company Scope
We sell WuXi ATU and WuXi Clinical WuXi MedKey by 2025.BusinessFocus on Facts。
| Index (million yuan) | FY2024 | FY2025 | Year 2026 |
|---|---|---|---|
| Sales (Total) | 39,241.4 | 45,456.2 | 28,897.5 |
| Our Business | 35,766.7 | 43,420.8 | 28,897.5 |
| WuXi Chemistry | 29,052.4 | 36,465.8 | 24,986.0 |
| TIDES | ― | 11,370 | 7,260 |
| Low development and manufacturing | ― | 19,920 | 14,990 |
| WuXi Testing | 3,860.6 | 4,041.7 | 2,480.6 |
| WuXi Biology | 2,543.9 | 2,677.2 | 1,391.9 |
| R&D expenses (co ous business) | 1,115.3 | 1,054.2 | 605.0 |
| Investment | 4,003.5 | 5,538.2 | 2,961.6 |
| Net income attributable to shareholders | 19 | 2025, year-end +105.2%. including profits such as business sale |
| 35,584 people | June 30, 2026. 33,834 people | |
| Remaining Orders (Co ous Business) | 664.3 billion yuan | June 30, 2026, year-end +25.2% |
| Maximum customer dependencies | 37.92% | Maximum customer ratio for 2025 sales. 48.11% of top 5 companies |
| Sales from US customers | 222.8 billion yuan | Year 2026 Approx. 77% of the continuous business (cal ating this article) |
| 2026 Outlook | Sales 585-605 billion yuan | August 2026 +35-39% |
One of the biggest customers37.92% FactsHome Annual ReportWe do not disclose the name of the customer to the customer. Undetermined / FutureHome The growth of certain drugs by linking this concentration and TIDES growth is not discussed in this article as it exceeds the primary information range. Additionally, TIDES sales only include annual numbers.The breakdown of peptide and nucleic acid is not disclosed。
5. Drug discovery and DDS resources
| Resource Types | ||
|---|---|---|
| Home | 35,584 employees TIDES and peptides | Facts |
| Equipment (Peptide) | Total capacity of solid-phase peptide reactorOver 100,000LHome Construction of peptide equipment of Taixing (Jiangsu Province) completed earlier than scheduled in September 2025 | Facts |
| Equipment (low original medicine) | Total capacity of reaction tanks for low-priority drugsOver 4,000kL(2025 year-end). In 2025, the original drug base of Changzhou, Taixing, and Jinshan passed the U.S. FDA inspection without pointing out | Facts |
| Gold (Investment) | Capital investment of 2025 yuan 55.4 billion. 202675 to 85 billion yuan(originally 65–75 billion yuan) Construction of new bases in Changzhou | Facts |
| Gold (R&D expenses) | Co ing business: 10.5 billion yuan (2025). Research and development costs for contracted companies, not research and development costs for new drugs | Facts |
| In August 2025, a new H strain was issued and $76.5 billion was issued. An explanation that about global expansion and equipment construction is used. | Facts | |
| ADC Contractor WuXi XDC Cayman Dec ed to the end of 2024 30.33%→2025 18.55%. Partial sale and di by the increase of the other party) | Facts | |
| Sell (Select and Focus) | Received a contract for cell and gene therapy (WuXi ATU’s U.S.-English and Chinese business) for clinical trials (WuXi Clinical WuXi MedKey, to Hillhouse in December 2025) | Facts |
| Public Funds | Revenue of R&D subsidy from each country, etc. Unknown for TIDES | Facts |
| Technology Introduction (Lic)) | peptides and nucleic acid technologies are not included in annual report and intermediate report. | Not confirmed |
| Collaboration with universities and research institutions | Joint research with universities on peptide and nucleic acid is not included in annual report and intermediate report | Not confirmed |
Annual report as TIDES technologyThin film capac s, extrafiltration (TFF) / deposition, continuous flow purificationHome FactsHome Peptides connect amino acids one by one on the grain of resinSolid Phase SynNucleic acid is commonly used to connect the base one by one on a solid carrier, BothWash with a large amount of solvent per reactionFeatures Therefore, afterHow fast to remove solvents (thin film)、How to extract only the desired length (filtration, deposition, chromatography)Home Set the production volume and cost directly. The capacity of the reaction tank (over 100,000 L) tends to be noticed, but from the position of the material and process,resins and solvents along with amino acids and protective bases, and fillers for refining collectionIt is an area that is easy to secure. The company does not disclose which solvents and resins are used, and this is a general explanation of this article.
6. Past Initiatives
| Time | Home | |
|---|---|---|
| December 2000 | Established WuXi PharmaTech | chemical compounds from a contract |
| Year 2018 | Listed in Shanghai in May and Hong Kong in December | Double listing of A and H shares |
| September 9, 2024 | BIOSECURE Bill (H.R. 8333)Close BGI/MGI/GIlete Genomics/WuXi AppTec/WuXi BiologicsNameHome | This bill is not established during the 118th parliament |
| 2024 views | TIDES' new equipment is launched sequentially | 2025 TIDES Sales Double Mounting |
| 2025 years | Sales of TIDES is $13.7 billion (+96.0%)Home TIDES customer increased by 25%, the number increased by 45% | peptides and nucleic acids are one of the main businesses |
| August 2025 | Sura increased HK$76.5 billion by issuing new H shares | Expanding Facilities |
| September 2025 | Completed the peptide system of Taixing.Reaction tank of solid-phase peptide exceeds 100,000LHome | Expanded peptide mass production capacity |
| October 9, 2025 | In U.S. Senate’s meeting, Hagati membersIOSification of BIOSECURE Law to the National Defense LawA that asks for praise to | “biotechnology companies of concern” |
| December 15, 2025 | Completed sale of clinical trial commissioned WuXi Clinical and WuXi MedKey to Hillhouse | Focusing on CRDMO, centered on chemistry |
| 18 December 2025 | Public Law 119-60Home Article 851 Pro、ts government procurement from biotechnology companies with concerns.No specific company name | The target is the 1260H list of the Ministry of Defense and the structure of the list created by the administrative budget station (OMB). |
| June 8, 2026 | US Department of DefenseAdd WuXi AppTec to 1260H List (China Military Enterprise)(Federal Gazette dated June 10) | The company announced on June 9th |
| June 11, 2026 | Prosecuted the Ministry of Defense to the Federal District of Colombia. Disabling, canceling and deleting from the list | Legal disputes |
| August 7, 2026 | Federal District Court acknowledges the company's appeal,(dis sure on August 9 of the company) | Protected from direct profits by designation during the trial |
| August 2026 | 2026 sales forecast585 to 605Contact Us TIDES expects about +45% year-round | Orders are growing even in the reverse of regulations |
| August 24, 2026 | On the basis of WuXi Biology compound library (DEL)Unauthorized accessDisclosure occurs. Explanation that you have been enclosed and you have no regular business requirements | Manage customer data again |
7. Future plans and the handling of US SECURE laws
The company assumes these s as "description about the future" andInternational geopoli environment, legal limitations, judicial proceduresIdentify risks such as Facts。
What is the US SECURE Act?
To the extent that the primary material of the U.S. Congress and the body of laws and regulations have been confirmed,Must be confirmedHomeNot confirmed
| Contents confirmed by primary material | ||
|---|---|---|
| Legal | Public Law 119-60 December 18, 2025 Article 851 'Prohibition of Contract with Specific Biotechnology companies' | Facts |
| Name | Article 851No specific company nameHome H.R. 8333, which passed down the hospital in 2024, was named WuXi AppTec. | Facts |
| What is prohibited | Federal government agencies procure equipment and services of concerned biotechnology companies, contract with companies that use them, use them with subsidies and loan funds | Facts |
| How to decide a company with concern | (A) Ministry of Defense1260H List(B) Companies that are judged by the procedure of OMB and related to the equipment and services of biotechnology, (B) Companies that are judged to be under the control of foreign opponents in the procedure of OMB, (C) subsidiaries and parent companies etc. | Facts |
| Deadline for Procedure | OMBWithin 1 year from the establishment of lawto announce the list of target companies. Revised the Federal) Rules (FAR) within one year from the guidelines within 180 days | Facts |
| Prohibition starts | 1260H List60 days after the FAR revision(other than 90 days). Equipment and services based on contracts formed prior to the date of implementation may be subject to a elapsed failure to apply some bans for five years from the FAR revision | Facts |
| WuXi AppTec 1260H Specification | confessions specified in federal official report on June 10, 2026. The Ministry of Land, Infrastructure, Transport and Tourism (SASAC) expresses the basin of the country’s asset supervisory board (SASAC), which is voluntarily related to the National Defense Technology Industry Bureau (SASTIND) and the People’s Release Army. The company proclaims that the Federal District Court ordered a temporary intermittent on August 7th, contrary to the fact that it is not owned or controlled by the army or government and does not provide services to the army. | Facts |
| List of OMB | As of September 26, 2026, OMB's "A Concerned Biotechnology Company" list is not found in the federal official report. Deadline: December 18, 2026 | Undetermined / Future |
| WUXI AppTec | The list of OMBs, the protagonist of the interception extends to the procedure of Article 851, or the final conclusion of the litigationNot confirmed | Undetermined / Future |
| Pro ted | As of September 2026Pro ted Pro tedHome How to proceed at the start time | Undetermined / Future |
I couldn't check the following documents. Undetermined / Future。
Federal District CourtConcrete range(Instruction of the court itself) This paper is confirmed by the company's disclosure)/Ministry of DefenseAppeal/ OMBWhich companies are listed/TIDESBreakdown of peptide and nucleic acid salesHomeProduction Capacity/ New location in ChangzhouInvestment and Production CapacityHome As of September 2026, we will not be able to say that “the transaction with WuXi AppTec will be。 from ○”.
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| Contracted chemical (low , peptide, nucleic acid)management resources | The annual report “Concentration to the CRDMO strategy of the core” was sold to cells, gene therapy and clinical trials. | Facts |
| Peptide and Nucleic AcidThe second pillar following low-s | TIDES’ sales doubled in 2025 and expanded solid phase。 equipment to more than 100,000L. 2026 | |
| connect with customers at the stage of productionLifted s up to mass production | "Follow the" strategy, the number of researches transferred from research to development (310, 2025), the development and manufacturing (3,731) (end of June 2026) | |
| ADCWe do not have our own company, we are involved through our affiliates | ADC contract company WuXi XDC has lowered its ownership from 30.33% to 18.55% | |
| US regulationsBusiness continues while fighting by legal means | Prosecuted the 1260H specification and obtained a temporary stoppage. Reach sales forecasts and capital investment plans during the same period | Facts |
| In preparationDissolved medicines and injectionsClose | The annual report shows the expansion of oral formulations into aseptic injections, the study of spray drying, hot melt extrusion and lipid nanoparticles | Facts |
After being listed on the 1260H list in June 2026, the company announced its sales forecast in August513 to 530 billion yuan 585 to 585 billion yuanInvestment65–75 billion yuan 75–85 billion yuanContact Us FactsHome Approx. 77% of sales in the first half of 2026 are for US customers The calculation of this paperHome This article isWe have determined that the customer does not stop supplying already advanced、s until the conclusion of the regulationRead with the Table of Things Undetermined / FutureHome In Article 851, there are cases in which there is a elapsed amount that does not apply some bans for 5 years from the revision of the FAR for the contract tied before the date of enforcement. FactsHome However, there is a possibility of changing the flow of new orders in the conclusion of the list of OMB and litigation, and the primary material that indicates the judgment of the customer is not confirmed in this article.
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
| Scope | ||
|---|---|---|
| Peptide and Nucleic Acid (TIDES) | Consistently commissioned research and manufacture of oligonucleotides, peptides, and chemical bindings. Thin film capac s, TFF/sedimentation, continuous flow purification | Reaction tank of solid-phase peptide exceeds 100,000L |
| Low's original medicine | Process studies of flow chemistry, catal , crystallization, particle design. From the original medicine to preparation of high pharmacological activity drugs | Total capacity of 4,000 kL. Pipeline 3,731 s (including Commercial 95, Phase III 94) |
| Expanded from oral preparation to aseptic injection. Research on the preparation of difficult-to-melt drugs (spray drying, hot melt extrusion), lipid nanoparticles | No disclosure | |
| Search Syn | Syn and Delivery of New s | Over 440,000 in the past 12 months (as of the end of June 2026) |
| Test and Evaluation | Safety evaluation, drug delivery (DMPK), bio ity analysis. Developed in-house software to streamline nucleic acid and peptide metabolic identification | Facilities in Suzhou and Shanghai pass inspections such as U.S. FDA and PMDA |
| Drug Development | Evaluation of efficacy in test tubes and animals, and compound search by DNA code library (DEL) | Over 20% of new customers |
In the company's disclosure, the reaction tank of low- original medicine isOver 4,000kL (over 4 million L)Reaction tank of solid phase peptideOver 100,000LThere are two numbers. FactsHome Compared to numbers, low s look 40 times larger.Different types of equipmentI can't compare it simply. The reaction tank of low's is a pot that reacts by mixing liquids. The reaction tank of peptide solid phase's isPut the resin particle and put the reagent and solvent for washing again and againContainer Solid phase determines the amount of time per b。 and the amount of solvent to be used for filtration, susceptibility, and cleaning. "100,000L" is a number that indicates that the company is fully divided into peptides.Does not correspond directly to the amount of peptides that can be selected (kg)Note: The company does not disclose annual production of peptides Undetermined / Future。
11. Risks that this company has
| Risks | ||
|---|---|---|
| US Regulations | Con、 of litigation for 1260H designation, listing of OMBs, and scope of prohibition of procurement after FAR revision are not confirmed | Undetermined / Future |
| US customer dependencies | Approx. 77% of sales in the first half of 2026 were for US customers (222.8 billion yuan / 288.98 billion yuan) | The calculation of this paper |
| Dependency on large customers | 37.92% of sales, 48.11% of top five companies | Facts |
| Information Security | In August 2026, WuXi Biology’s compound library is unauthorised access. Explanation that the company has been enclosed and has no data public or misuse evidence | Facts |
| The majority of the sales are US dollars, and the company itself says that it decreases the sales of the original building when it comes to the high | Facts | |
| Rapid expansion rebound | The equipment is increased by the front. If the customer’s demand and regulatory conclusions are not expected, the operating rate may be lower |
12. Glossary
- CRDMO
- Research and Development Organization A company that deals with production, development and manufacturing.
- TIDES
- Name of WuXi AppTec's business dealing with oligonucleotide (nucleic acid) and peptide.
- Solid-phase peptide
- How to assemble peptides by combining amino acids one by one in the grain of resin. Wash with solvent every time the reaction.
- Origonucleotide
- A short nucleic acid with dozens of bases. The body of nucleic acid drugs such as antis and siRNA.
- 1260H List
- List of "Chinese Military Companies in the United States" published annually by the U.S. Department of Defense.
- BIOSECURE
- A common name of a bill that limits U.S. government procurement from a concerned biotechnology company. In this article, we call Article 851 of the National Defense Law, which was established in December 2025.
- FAR
- Federal Acquisition Regulation. Rules stipulated by the U.S. federal government's procurement rules.
- A court order that temporarily stops the execution of the opponent's actions until the conclusion of the court.
Concept diagram of AI generation13. Source
- WuXi AppTec Co., Ltd. 2025 Annual Report Business overview, divisional and regional sales, TIDES sales and solid-phase equipment, low- equipment and inspection, research and development costs, capital investment, number of employees, maximum customer ratio, issuance of H shares, ownership of WuXi XDC, business sale, government subsidies, formulation and TIDES technology, company history and listing. https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040101920.pdf
- WuXi AppTec Co., Ltd. Interim Report 2026 Sales by department and region, TIDES sales and s, low-pipeline pipelines, 2026 equipment and capital investments, number of employees, R&D, 1260H designation and litigation, risk factors. https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0904/2026090400640.pdf
- WuXi AppTec Co., Ltd. Voluntary Announcement (June 9, 2026). The designation of the 1260H list of the Ministry of Defense and its rebellion. https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0609/2026060900095.pdf
- WuXi AppTec Co., Ltd. Voluntary Announcement — Litigation (June 11, 2026). Prosecution and claims for the Federal District of Colombia. https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0611/2026061101697.pdf
- WuXi AppTec Co., Ltd. Announcement for Preliminary Injunction Decision of temporary closure (July 22), deter of temporary closure (August 7). https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0809/2026080900009.pdf
- WuXi AppTec Co., Ltd. Voluntary Announcement (August 24, 2026). Unauthorized access on the DEL base of WuXi Biology. https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0824/2026082401999.pdf
- U.S. Department of Defense Notice of Availability of Designation of Chinese Military Companies Addition to 1260H list (including WuXi AppTec) and the basis specified, the procedure for re-exa。. https://www.federalregister.gov/documents/2026/06/10/2026-11571/notice-of-availability-of-designation-of-chinese-military-companies
- U.S. Congress (GovInfo) Public Law 119-60, National Defense Authorization Act for Fiscal Year 2026 Pro ted content, the definition of a concerned biotechnology company, the list of OMB guidelines, the deadline for FAR revisions, the time of enforcement, and the progress. https://www.govinfo.gov/content/pkg/PLAW-119publ60/html/PLAW-119publ60.htm
- U.S. Congress (GovInfo) October 9, 2018 Hagerty-Peters amendment https://www.govinfo.gov/content/pkg/CREC-2025-10-09/html/CREC-2025-10-09-pt1-PgS7062-3.htm
- U.S. Congress (GovInfo) H.R. 8333, BIOSECURE Act A statement that refers to WuXi AppTec as a biotechnology company with concern. https://www.govinfo.gov/content/pkg/BILLS-118hr8333eh/html/BILLS-118hr8333eh.htm
- WuXi AppTec Co., Ltd. Official website (the source of logo image). https://www.wuxiapptec.com/
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Official name, predecessor established (December 2000), head office and registered office, listed on Shanghai and Hong Kong (2018) | Facts | Source 1 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040101920.pdf |
| Sales by department (2024 to 2025), total and continuous business sales, net income, R&D expenses, capital investment, employees 33,834 | Facts | Source 1 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040101920.pdf |
| TIDES sales 11.3 billion yuan (+96.0%), customer + 25%, molecule number + 45%, solid-phase peptide reaction tank 100,000L and Taixing completed (September 2025) | Facts | Source 1 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040101920.pdf |
| Reaction tank of low's primary drug 4,000 kL, FDA inspection, compound of more than 420,000, 310 molecules from research to development, sales of low's development and manufacturing 199.2 billion yuan | Facts | Source 1 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040101920.pdf |
| Sales by region (2025, US customers 312.5 billion yuan), up to 37.92%, up to 5 companies 48.11% | Facts | Source 1 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040101920.pdf |
| WuXi XDC'sity (30.33%→18.55%), WuXi ATU and sale of clinical trial contracts, issuance of H shares (about $76.5 billion), recurring revenue of government subsidies | Facts | Source 1 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040101920.pdf |
| Technology of TIDES and preparation (thin film evaporation, TFF/sedimentation, continuous flow purification, spray drying, hot melt extrusion, lipid nanoparticles), concentration to the core CRDMO | Facts | Source 1 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040101920.pdf |
| Sales by department, TIDES 72.6 billion yuan (+44.3%), Pipeline 3,731), Revenue 664.3 billion yuan,35 35,584 people, R&D expenses, capital investment | Facts | Source 2 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0904/2026090400640.pdf |
| 2026 Sales, capital investment, and adjustment of FCF risks, TIDES forecasts + 45%, risks assumed for's | Facts | Source 2 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0904/2026090400640.pdf |
| Sales from US customers in the first half of 2026 $22.8 billion | Facts | Source 2 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0904/2026090400640.pdf |
| US Customer Ratio (20.72% for 2025, period for 2026) | The calculation of this paper | The number of source 1 and 2 is divided by this article |
| 1260H List and the basis indicated by the Ministry of Defense, the company's rebellion | Facts | Source 3・7 https://www.federalregister.gov/documents/2026/06/10/2026-11571/notice-of-availability-of-designation-of-chinese-military-companies |
| Federal District Court Prosecution (June 11, 2026) | Facts | Source 4 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0611/2026061101697.pdf |
| Determination, Deliberation and Deter (August 7, 2026) | Facts | Source 5 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0809/2026080900009.pdf |
| Unauthorized access and description of the company on the DEL platform | Facts | Source 6 https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0824/2026082401999.pdf |
| The date of establishment of Article 851, the content of prohibition, the definition of the concerned company (1260H), the expiration date of OMB/FAR, the time of enforcement (after 60 days and 90 days), the company name will not be stated after the 5 years. | Facts | Source 8 https://www.govinfo.gov/content/pkg/PLAW-119publ60/html/PLAW-119publ60.htm |
| Explanation of the SECURE method at the hospital (October 9, 2025) | Facts | Source 9 https://www.govinfo.gov/content/pkg/CREC-2025-10-09/html/CREC-2025-10-09-pt1-PgS7062-3.htm |
| H.R. 8333 named WuXi AppTec | Facts | Source10 https://www.govinfo.gov/content/pkg/BILLS-118hr8333eh/html/BILLS-118hr8333eh.htm |
| Treating Article 851 of the National Defense Law as "SESECURE Law" | The calculation of this paper | 。 by this article. Corres ence from the revision of the source 9 and the article of the source 8 is the same term and mechanism |
| Drug /DDS Classification (Pharmaceu /DDS Biotech/Contract Development) | The calculation of this paper | This article. Company name is an example of a company handled by this series. |
| The list of OMB does not appear in federal official reports as of September 26, 2026 | Undetermined / Future | Search results for federal officials. I can not confirm whether or not public announcements other than official reports |
| WuXi AppTec will be subject to Article 851, scope of temporary closure, conclusion of litigation, start time of procurement prohibition | Undetermined / Future | Not confirmed at the time of source 2, 5, and 8. This article does not break out the's https://www.govinfo.gov/content/pkg/PLAW-119publ60/html/PLAW-119publ60.htm |
| Maximum customer name and supply item, TIDES peptide and nucleic acid breakdown, peptide annual production, investment amount and capacity of Changzhou new base | Undetermined / Future | Not listed in Source 1 and 2. Not in this article https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0904/2026090400640.pdf |
| Technical introduction of peptide and nucleic acid, joint research with universities | Undetermined / Future | Not listed in Source 1 and 2. This article does not break even if it is not present https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040101920.pdf |
| The peptides and nucleic acids are made into the second pillar, and the peptides raised are lifted up to mass production. | Explanation of TIDES' growth strategy and interpretation of this article from changes in the ownership of WuXi XDC | |
| Read that customers are making decisions to stop supplying to regulatory conclusions | Interpretation of this paper from the progress of the article. The primary material of the customer is not confirmed. | |
| Explanation of the meaning of solid phase and reaction tank capacity, rapid expansion rebound risk | General technical commentary and interpretation of this paper from equipment planning |
Last Updated:September 26, 2026/Troy Technical
All figures in this article are based on the annual report, interim report and disclosure document submitted by WuXi AppTec Co., Ltd. to the Hong Kong Exchange, the official record of federal official reports of the United States, laws and regulations and parliament (GovInfo). We do not use estimates and media-based numbers of survey companies. This article is an interpretation from the primary information and is not published by the company or the U.S. government. The explanation of laws and regulations is based on articles and publications as of September 26, 2026, and is not legal advice. This paper is based on the business content of the company and does not recommend the use or effect of certain drugs.